Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
HIV
Renal function
Tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
eGFR
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
received:
21
02
2021
accepted:
26
11
2021
entrez:
8
12
2021
pubmed:
9
12
2021
medline:
4
2
2022
Statut:
epublish
Résumé
Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is known to be relatively safe to the kidneys. However, the changes in renal function under long-term use of TAF are not known. In this study, we evaluated renal function in Japanese HIV-1-positive patients switching to TAF after long-term treatment with TDF. A single-center observational study was conducted in Japanese HIV-1-positive patients. TDF was switched to TAF after at least 48 weeks of the treatment so we could evaluate the long-term use of TDF. The primary endpoint was the estimated glomerular filtration rate (eGFR) at 144 weeks of TAF administration. In addition, we predicted the factors that would lead to changes in eGFR after long-term use of TAF. Of the 125 HIV-1-positive patients who were prescribed TAF at our hospital during the study period, 70 fulfilled the study criteria. The eGFR at the time of switching from TDF to TAF was 81.4 ± 21.1 mL/min/1.73 m In this study, it was confirmed that switching to TAF was effective for Japanese HIV-1-positive patients who had been taking TDF for a long period of time and had a reduced eGFR. It was also found that the transition status depended on the eGFR and weight at the time of switch. Since HIV-1-positive patients in Japan are expected to continue taking TAF for a long time, renal function and body weight should be carefully monitored.
Sections du résumé
BACKGROUND
Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is known to be relatively safe to the kidneys. However, the changes in renal function under long-term use of TAF are not known. In this study, we evaluated renal function in Japanese HIV-1-positive patients switching to TAF after long-term treatment with TDF.
METHODS
A single-center observational study was conducted in Japanese HIV-1-positive patients. TDF was switched to TAF after at least 48 weeks of the treatment so we could evaluate the long-term use of TDF. The primary endpoint was the estimated glomerular filtration rate (eGFR) at 144 weeks of TAF administration. In addition, we predicted the factors that would lead to changes in eGFR after long-term use of TAF.
RESULTS
Of the 125 HIV-1-positive patients who were prescribed TAF at our hospital during the study period, 70 fulfilled the study criteria. The eGFR at the time of switching from TDF to TAF was 81.4 ± 21.1 mL/min/1.73 m
CONCLUSIONS
In this study, it was confirmed that switching to TAF was effective for Japanese HIV-1-positive patients who had been taking TDF for a long period of time and had a reduced eGFR. It was also found that the transition status depended on the eGFR and weight at the time of switch. Since HIV-1-positive patients in Japan are expected to continue taking TAF for a long time, renal function and body weight should be carefully monitored.
Identifiants
pubmed: 34876151
doi: 10.1186/s12981-021-00420-5
pii: 10.1186/s12981-021-00420-5
pmc: PMC8650504
doi:
Substances chimiques
Anti-HIV Agents
0
Fumarates
0
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Informations de copyright
© 2021. The Author(s).
Références
Lancet HIV. 2016 Apr;3(4):e158-65
pubmed: 27036991
AIDS Res Ther. 2019 Dec 7;16(1):40
pubmed: 31810490
Int J Infect Dis. 2020 Mar;92:71-77
pubmed: 31884172
Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304
pubmed: 17005808
AIDS. 2014 Aug 24;28(13):1903-10
pubmed: 25259702
AIDS. 2016 Jun 19;30(10):1563-71
pubmed: 26919734
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
Mol Pharm. 2013 Feb 4;10(2):459-66
pubmed: 22738467
Am J Kidney Dis. 2011 May;57(5):773-80
pubmed: 21435764
Lancet. 2015 Jun 27;385(9987):2606-15
pubmed: 25890673
Lab Invest. 2011 Jun;91(6):852-8
pubmed: 21403643
Kidney Int. 2010 Dec;78(11):1171-7
pubmed: 20811330
AIDS. 2019 Jul 15;33(9):1455-1465
pubmed: 30932951
Ann Intern Med. 2021 Jun;174(6):758-767
pubmed: 33721521
J Int AIDS Soc. 2021 Apr;24(4):e25702
pubmed: 33838004
Open Forum Infect Dis. 2019 Oct 04;6(10):ofz414
pubmed: 31660372
Hypertens Res. 2008 Aug;31(8):1559-64
pubmed: 18971530
N Engl J Med. 2006 Jan 19;354(3):251-60
pubmed: 16421366
Vasc Health Risk Manag. 2009;5(1):315-20
pubmed: 19436662
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):416-22
pubmed: 26962850
J Infect Chemother. 2012 Apr;18(2):169-74
pubmed: 21968965
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55
pubmed: 23807155
Kidney Int. 2013 Sep;84(3):622-3
pubmed: 23989362
J Infect Dis. 2020 Jul 23;222(4):637-645
pubmed: 32189003
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088